Clinical Trials Directory

Trials / Terminated

TerminatedNCT01141881

Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema

Evaluation of the Role of Intravitreal Injection of TPA in Treatment of Refractory Diabetic Macular Edema

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
Sponsor
Mashhad University of Medical Sciences · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen activator(tPA) in treatment of refractory diabetic macular edema(DME).

Conditions

Interventions

TypeNameDescription
DRUGTissue Plasminogen Activator,bevacizumab ,follow up25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing

Timeline

Start date
2009-05-01
Primary completion
2010-01-01
Completion
2010-03-01
First posted
2010-06-11
Last updated
2010-10-08

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT01141881. Inclusion in this directory is not an endorsement.

Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema (NCT01141881) · Clinical Trials Directory